Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Deferred Taxes: 2022-2025

Historic Deferred Taxes for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Sep 2025 value amounting to $255,000.

  • Centessa Pharmaceuticals' Deferred Taxes fell 79.67% to $255,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 26.97%. This contributed to the annual value of $2.7 million for FY2024, which is 110.00% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Deferred Taxes of $255,000 as of Q3 2025, which was down 75.15% from $1.0 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Deferred Taxes high stood at $1.3 million for Q3 2024, and its period low was -$23.5 million during Q2 2023.
  • Moreover, its 3-year median value for Deferred Taxes was $416,000 (2024), whereas its average is -$2.2 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Deferred Taxes crashed by 2,040.74% in 2023 and then spiked by 367.11% in 2024.
  • Centessa Pharmaceuticals' Deferred Taxes (Quarterly) stood at -$2.8 million in 2022, then surged by 94.63% to -$149,000 in 2023, then spiked by 367.11% to $398,000 in 2024, then slumped by 79.67% to $255,000 in 2025.
  • Its Deferred Taxes stands at $255,000 for Q3 2025, versus $1.0 million for Q2 2025 and $995,000 for Q1 2025.